X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The research explores the identification of mAbs working against a pro-inflammatory protein mediator, pCTS-L. These anti-pCTS-L monoclonal antibodies may provide effective therapies for the clinical treatment of human sepsis and other infectious diseases, including COVID-19.
Lead Product(s): Undisclosed
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 03, 2023
Details:
The results from this trial show that BIIB059 (litifilimab) may effectively block the body’s production of harmful inflammatory molecules in people with SLE, easing their joint pain and improving overall disease activity.
Lead Product(s): Litifilimab
Therapeutic Area: Immunology Product Name: BIIB059
Highest Development Status: Phase IIIProduct Type: Large molecule
Recipient: Biogen
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 15, 2022
Details:
The preclinical study published that Pepcid (famotidine), a histamine 2 receptor (H2R) antagonist, prevents cytokine storm in mice, famotidine did this indirectly because it stimulated signals caused by vagus nerve, a major nerve into the body’s organs.
Lead Product(s): Famotidine
Therapeutic Area: Infections and Infectious Diseases Product Name: Pepcid
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 19, 2022
Details:
Famotidine is a safe, low-cost, over-the-counter drug usually used to treat heartburn. People with Covid-19 often get sick because the body’s inflammatory response to the virus gets overactivated.
Lead Product(s): Famotidine
Therapeutic Area: Infections and Infectious Diseases Product Name: Pepcid
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 09, 2022
Details:
The findings published in the JAMA Psychiatry showed that after two weeks of daily treatment, women treated with zuranolone had a statistically significant reduction in their core symptoms of depression compared to women who received a placebo.
Lead Product(s): Zuranolone
Therapeutic Area: Psychiatry/Psychology Product Name: SAGE-217
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 30, 2021
Details:
Results from the study showed that the most effective treatment was the combination of corticosteroids-such as dexamethasone – with tocilizumab when compared to standard of care.
Lead Product(s): Dexamethasone,Tocilizumab
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 20, 2020
Details:
The three Feinstein Institutes trials are offered to patients already admitted to Northwell Health hospitals with moderate to severe COVID-19.
Lead Product(s): Remdesivir
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 20, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
